Size : | Price | Quantity | |
---|---|---|---|
5 mg | $40.00 | ||
25 mg | $135.00 |
Ibudilast (50847-11-5) is a phosphodiesterase inhibitor with some selectivity for PDE4 and 5. (IC50s= 53, 35, 48, 12 and 10 μM for PDE 1a, 2, 3, 4 and 5 respectively1). Acts as a cerebral vasodilator by selectively inducing a cGMP-independent relaxation of the intracranial vertebrobasilar artery.2 Attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma via PKA signaling.3 A glial cell activation inhibitor.4 Enhances morphine analgesia and attenuates tolerance and withdrawal.5 Orally active and crosses the blood-brain barrier.5
References/Citations:
1) Kishi et al. (2001), Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall; Cardiovasc. Drug Rev., 19 215
2) Yamazaki et al. (2011), Ibudilast. A mixed PDE3/4 inhibitor, causes a selective and nitric oxide/cGMP-independent relaxation of the intracranial vertebrobasilar artery; Eur. J. Pharmacol., 650 605
3) Cueva Vargas et al. (2016), The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling.; Neurobiol. Dis., 93 156
4) Mizuno et al. (2004), Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia; Neuropharmacology, 46 404
5) Ledeboer et al. (2007), Ibudilast (AV-411). A class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes; Expert. Opin. Investig. Drugs, 16 935
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Ibudilast (50847-11-5) is a phosphodiesterase inhibitor with some selectivity for PDE4 and 5. (IC50s= 53, 35, 48, 12 and 10 μM for PDE 1a, 2, 3, 4 and 5 respectively1). Acts as a cerebral vasodilator by selectively inducing a cGMP-independent relaxation of the intracranial vertebrobasilar artery.2 Attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma via PKA signaling.3 A glial cell activation inhibitor.4 Enhances morphine analgesia and attenuates tolerance and withdrawal.5 Orally active and crosses the blood-brain barrier.5
References/Citations:
1) Kishi et al. (2001), Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall; Cardiovasc. Drug Rev., 19 215
2) Yamazaki et al. (2011), Ibudilast. A mixed PDE3/4 inhibitor, causes a selective and nitric oxide/cGMP-independent relaxation of the intracranial vertebrobasilar artery; Eur. J. Pharmacol., 650 605
3) Cueva Vargas et al. (2016), The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling.; Neurobiol. Dis., 93 156
4) Mizuno et al. (2004), Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia; Neuropharmacology, 46 404
5) Ledeboer et al. (2007), Ibudilast (AV-411). A class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes; Expert. Opin. Investig. Drugs, 16 935
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.